Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer
(BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating
tumour cells (CTC) in peripheral blood.
Eligible patients will be randomised in 1:1 ratio to either the trastuzumab arm or the
observation arm.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC